Skip to main content
  1. Home

Process

Valid for Measure Submission
✔

Combination chemotherapy or chemo-immunotherapy (if HER2 positive), is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0 or stage IB - III hormone receptor negative breast cancer

  • Percentage of female patients, age >= 18 and < 70 at diagnosis, who have their first diagnosis of cancer (epithelial malignancy), at AJCC stage T1cN0M0 or Stage IB - IIIC, whose primary tumor is of the breast, and progesterone and estrogen receptor negative is recommended or administered multi-agent chemotherapy within 4 months (120 days) of diagnosis

    CBE ID
    0559

Communication with the physician or other clinician managing on-going care post fracture for men and women aged 50 years and older

  • Percentage of adults 50 years and older treated for a fracture with documentation of communication, between the physician treating the fracture and the physician or other clinician managing the patient’s on-going care, that a fracture occurred and that the patient was or should be considered for osteoporosis treatment or testing. This measure is reported by the physician who treats the fracture and who therefore is held accountable for the communication.

    CBE ID
    0045

Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports

  • Percentage of final reports for CT or MRI studies of the brain performed within 24 hours of arrival to the hospital for patients aged 18 years and older with the diagnosis of ischemic stroke or TIA or intracranial hemorrhage that includes documentation of the presence or absence of each of the following: hemorrhage and mass lesion and acute infarction.

    CBE ID
    0246

Concurrent Use of Opioids and Benzodiazepines (COB)

  • The percentage of individuals >=18 years of age with concurrent use of prescription opioids and benzodiazepines during the measurement year.

    A lower rate indicates better performance.

    CBE ID
    3389